Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
24,683,081

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Exelixis (EXEL) Earnings, Revenues Beat Estimates in Q4

Exelixis's (EXEL) earnings and revenues beat expectations in the fourth quarter on strong sales of Cabometyx.

Bristol-Myers' Sprycel Gets European Nod for Label Expansion

Bristol-Myers' (BMY) oncology drug, Sprycel in combination with chemotherapy gets EC approval to treat pediatric patients with newly diagnosed Ph+ ALL.

Pfizer sBLA for Kidney Cancer Drug Combo Gets Priority Review

Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets priority review in the United States. The decision is expected in June.

Stock Market News For Feb 12, 2019

Markets closed mostly higher on Monday as fresh rounds of trade talks between the United States and China began.

Lilly to Begin Exchange Offer for Sale of Balance Elanco Stake

Eli Lilly (LLY) to initiate an exchange offer for shareholders to divest its remaining ownership interest in Elanco

Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs

Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.

Swarup Gupta headshot

Dow 30 Stock Roundup: Disney Earnings Impress, Pfizer's Cancer Drug Gets CHMP Nod

The index endured a mixed week after trade war fears reemerged.

Glaxo (GSK) Beats on Q4 Earnings, to Focus on Oncology in '19

Glaxo (GSK) beats earnings and sales estimates in the fourth quarter. Strong sales growth of vaccine portfolio boosts sales. However, Advair generic will severely impact the drug's U.S. sales.

Swarup Gupta headshot

Winners & Losers from Trump's State of the Union Address

While pharma majors could face greater scrutiny on drug pricing, defense, infrastructure and energy are likely to emerge as big winners.

Lilly/Incyte's Olumiant Meets Endpoint in Eczema Studies

Eli Lilly and Company (LLY) and partner Incyte's Olumiant meets primary endpoint in two phase III studies evaluating it for moderate-to-severe atopic dermatitis.

Pfizer's (PFE) New Lung Cancer Drug Vizimpro Gets CHMP Nod

Pfizer's (PFE) new lung cancer medicine, Vizimpro (dacomitinib) gets recommendation from CHMP of the EMA.

The Zacks Analyst Blog Highlights: Boeing, Thermo Fisher, Anthem, PayPal and Pfizer

The Zacks Analyst Blog Highlights: Boeing, Thermo Fisher, Anthem, PayPal and Pfizer

Swarup Gupta headshot

Dow 30 Stock Roundup: MCD, BA, 3M, MSFT, PFE, V Earnings Impress

The index enjoyed a strong week overall, bolstered by encouraging earnings.

Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY

Pfizer (PFE), Allergan (AGN), AbbVie (ABBV) and Novartis (NVS) report Q4 results.

Mark Vickery headshot

Top Analyst Reports for Boeing, Thermo Fisher & Anthem

Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), Thermo Fisher (TMO) and Anthem (ANTM).

Merck's Pneumococcal Vaccine Gets Breakthrough Therapy Status

Merck's (MRK) investigational pneumococcal vaccine V114 gets FDA's Breakthrough Therapy designation for prevention of invasive pneumococcal disease.

Company News For Jan 30, 2019

Companies In The News Are: HOG,XRX,PFE,HCA

Lilly/Pfizer's Osteoarthritis Pain Drug Succeeds in 2nd Study

Eli Lilly (LLY) and Pfizer announce that their investigational pain candidate, tanezumab, achieves significant reduction in pain in osteoarthritis patients in second late-stage study.

Amgen (AMGN) Q4 Earnings Beat Estimates, 2019 Guidance Tepid

Amgen (AMGN) beats estimates for both earnings and sales in Q4. Its forecast for 2019 disappoints investors Stock dips 2.4% in after-hours trading.

Ryan McQueeney headshot

Apple Earnings Preview & Latest Results from Verizon, 3M, and Pfizer

Ryan McQueeney recaps earnings results from Verizon, 3M, Pfizer, and Harley-Davidson. Later, he previews the upcoming report of sputtering tech behemoth Apple.

Apple To Report Fiscal Q1 Earnings

Apple To Report Fiscal Q1 Earnings

Mark Vickery headshot

The Apple (AAPL) of Investors' Eye

With Apple (AAPL) reporting fiscal Q1 earnings results after the closing bell this afternoon, this is where the majority of attention will be.

Pfizer (PFE) Q4 Earnings Beat, 2019 View Tepid, Stock Dips

Pfizer's (PFE) fourth-quarter earnings and sales beat estimates. Its forecast for 2019 falls short of expectations. Stock dips 2% in pre-market trading.

Pfizer (PFE) Q4 Earnings & Sales Beat, 2019 View Disappoints

Pfizer's (PFE) fourth-quarter earnings and sales beat estimates. 2019 forecast falls short of expectations. Stock dips 2% in pre-market.

Drug/Biotech Stock Earnings on Jan 29: PFE, AMGN, BIIB & AGN

Four drug/biotech stocks are scheduled to release their fourth-quarter results on Jan 29. Let's take a look at how these companies are poised ahead of their earnings release.